![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study Who Switched Off Suppressive Oral Daily ART
|
|
|
AIDS 2024 July 20-26 Munich
Celia Jonsson-Oldenbüttel1, Sebastian Noe1, Christoph Wyen2, Jan Borch3, Kevin Ummard-Berger4, Nils Postel5, Stefan Scholten6, Kathrin M. Dymek7, Bernd Westermayer8,
Patricia de los Rios9, Jenny Scherzer7
1MVZ München am Goetheplatz, Munich, Germany; 2Praxis am Ebertplatz, Cologne, Germany; 3Praxis Goldstein, Berlin, Germany; 4UBN/Praxis, Berlin, Germany; 5Prinzmed, Practice for Infectious Diseases, Munich, Germany; 6Praxis Hohenstaufenring, Cologne, Germany; 7ViiV Healthcare, Munich, Germany; 8GSK, Munich, Germany; 9ViiV Healthcare, Montreal, Canada
![0729241](../images/072924/072924-12/0729241.gif)
![0729242](../images/072924/072924-12/0729242.gif)
![0729243](../images/072924/072924-12/0729243.gif)
![0729244](../images/072924/072924-12/0729244.gif)
![0729245](../images/072924/072924-12/0729245.gif)
![0729246](../images/072924/072924-12/0729246.gif)
![0729247](../images/072924/072924-12/0729247.gif)
![0729248](../images/072924/072924-12/0729248.gif)
![0729249](../images/072924/072924-12/0729249.gif)
![07292410](../images/072924/072924-12/07292410.gif)
![07292411](../images/072924/072924-12/07292411.gif)
![07292412](../images/072924/072924-12/07292412.gif)
![07292413](../images/072924/072924-12/07292413.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|